These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

111 related items for PubMed ID: 7671188

  • 1. Inhibition by BMS 186295, a selective nonpeptide AT1 antagonist, of adrenal catecholamine release induced by angiotensin II in the dog in vivo.
    Martineau D, Yamaguchi N, Briand R.
    Can J Physiol Pharmacol; 1995 Apr; 73(4):459-64. PubMed ID: 7671188
    [Abstract] [Full Text] [Related]

  • 2. BMS-180560, an insurmountable inhibitor of angiotensin II-stimulated responses: comparison with losartan and EXP3174.
    Dickinson KE, Cohen RB, Skwish S, Delaney CL, Serafino RP, Poss MA, Gu Z, Ryono DE, Moreland S, Powell JR.
    Br J Pharmacol; 1994 Sep; 113(1):179-89. PubMed ID: 7812609
    [Abstract] [Full Text] [Related]

  • 3. Functional role of local angiotensin-converting enzyme (ACE) in adrenal catecholamine secretion in vivo.
    Yamaguchi N, Martineau D, Lamouche S, Briand R.
    Can J Physiol Pharmacol; 1999 Nov; 77(11):878-85. PubMed ID: 10593661
    [Abstract] [Full Text] [Related]

  • 4. Role of angiotensin AT1 and AT2 receptors in mediating the renal effects of angiotensin II in the anaesthetized dog.
    Clark KL, Robertson MJ, Drew GM.
    Br J Pharmacol; 1993 May; 109(1):148-56. PubMed ID: 8495237
    [Abstract] [Full Text] [Related]

  • 5. Inhibition of the haemodynamic effects of angiotensin II in conscious rats by AT2-receptor antagonists given after the AT1-receptor antagonist, EXP 3174.
    Widdop RE, Gardiner SM, Kemp PA, Bennett T.
    Br J Pharmacol; 1992 Nov; 107(3):873-80. PubMed ID: 1472980
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Lack of a centrally-mediated antihypertensive effect following acute or chronic central treatment with AT1-receptor antagonists in spontaneously hypertensive rats.
    Bunting MW, Widdop RE.
    Br J Pharmacol; 1995 Dec; 116(8):3181-90. PubMed ID: 8719794
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Pharmacological profile of valsartan: a potent, orally active, nonpeptide antagonist of the angiotensin II AT1-receptor subtype.
    Criscione L, de Gasparo M, Bühlmayer P, Whitebread S, Ramjoué HP, Wood J.
    Br J Pharmacol; 1993 Oct; 110(2):761-71. PubMed ID: 8242249
    [Abstract] [Full Text] [Related]

  • 10. Effects of systemic treatment with irbesartan and losartan on central responses to angiotensin II in conscious, normotensive rats.
    Culman J, von Heyer C, Piepenburg B, Rascher W, Unger T.
    Eur J Pharmacol; 1999 Feb 19; 367(2-3):255-65. PubMed ID: 10079000
    [Abstract] [Full Text] [Related]

  • 11. Inhibition of the acute effects of angiotensin II by the receptor antagonist irbesartan in normotensive men.
    Ribstein J, Picard A, Armagnac C, Sissmann J, Mimran A.
    J Cardiovasc Pharmacol; 2001 Apr 19; 37(4):449-60. PubMed ID: 11300658
    [Abstract] [Full Text] [Related]

  • 12. Influence of the angiotensin II AT1 receptor antagonist irbesartan on ischemia/reperfusion injury in the dog heart.
    Preckel B, Schlack W, Gonzàlez M, Obal D, Barthel H, Thämer V.
    Basic Res Cardiol; 2000 Oct 19; 95(5):404-12. PubMed ID: 11099168
    [Abstract] [Full Text] [Related]

  • 13. In vivo pharmacology of L-158,809, a new highly potent and selective nonpeptide angiotensin II receptor antagonist.
    Siegl PK, Chang RS, Mantlo NB, Chakravarty PK, Ondeyka DL, Greenlee WJ, Patchett AA, Sweet CS, Lotti VJ.
    J Pharmacol Exp Ther; 1992 Jul 19; 262(1):139-44. PubMed ID: 1625193
    [Abstract] [Full Text] [Related]

  • 14. Functional evidence for L-type Ca2+ channels controlling ANG II-induced adrenal catecholamine release in vivo.
    Martineau D, Briand R, Yamaguchi N.
    Am J Physiol; 1996 Dec 19; 271(6 Pt 2):R1713-9. PubMed ID: 8997374
    [Abstract] [Full Text] [Related]

  • 15. In vivo pharmacological characterization of UP 269-6, a novel nonpeptide angiotensin II receptor antagonist.
    Cazes M, Provost D, Versigny A, Cloarec A.
    Eur J Pharmacol; 1995 Sep 15; 284(1-2):157-70. PubMed ID: 8549620
    [Abstract] [Full Text] [Related]

  • 16. In vivo pharmacology of a novel AT1 selective angiotensin II receptor antagonist, MK-996.
    Kivlighn SD, Zingaro GJ, Gabel RA, Broten TP, Schorn TW, Schaffer LW, Naylor EM, Chakravarty PK, Patchett AA, Greenlee WJ.
    Am J Hypertens; 1995 Jan 15; 8(1):58-66. PubMed ID: 7734099
    [Abstract] [Full Text] [Related]

  • 17. Effects of irbesartan (SR47436/BMS-186295) on angiotensin II-induced pressor responses in the pithed rat: potential mechanisms of action.
    Christophe B, Libon R, Cazaubon C, Nisato D, Manning A, Chatelain P.
    Eur J Pharmacol; 1995 Aug 04; 281(2):161-71. PubMed ID: 7589203
    [Abstract] [Full Text] [Related]

  • 18. Inhibition by nifedipine of endothelin-induced adrenal catecholamine secretion in anesthetized dogs.
    Yamaguchi N.
    Can J Physiol Pharmacol; 1993 Aug 04; 71(3-4):301-5. PubMed ID: 8402396
    [Abstract] [Full Text] [Related]

  • 19. Dose-ranging study of the angiotensin II receptor antagonist irbesartan (SR 47436/BMS-186295) on blood pressure and neurohormonal effects in salt-deplete men.
    McIntyre M, MacFadyen RJ, Meredith PA, Brouard R, Reid JL.
    J Cardiovasc Pharmacol; 1996 Jul 04; 28(1):101-6. PubMed ID: 8797143
    [Abstract] [Full Text] [Related]

  • 20. Functional involvement of angiotensin AT2 receptor in adrenal catecholamine secretion in vivo.
    Martineau D, Lamouche S, Briand R, Yamaguchi N.
    Can J Physiol Pharmacol; 1999 May 04; 77(5):367-74. PubMed ID: 10535686
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.